Akero's Shares Soared 137% as Experimental NASH Drug Meets The Primary Endpoint In A Clinical Trial

Dow Jones2022-09-13

Shares of Akero Therapeutics Inc. soared 137.57% in premarket trading on Tuesday after the company said its experimental treatment for nonalcoholic steatohepatitis met a primary and secondary endpoint in a Phase 2b clinical trial.

NASH is a liver disease. "The magnitude and general consistency of results observed across the Phase 2a BALANCED and Phase 2b HARMONY studies increase the probability of success in Phase 3 and position EFX to potentially be a foundational monotherapy for patients with NASH," Dr. Stephen Harrison, one of the study's investigators, said in a news release.

Akero's stock is down 42.0% this year through Monday's close, while the broader S&P 500 has declined 13.7%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

evauoz
2022-09-14
evauoz
Buy?
lilynguyen
2022-09-13
lilynguyen
Ok
KYBoo
2022-09-13
KYBoo
Hjhh
- KYBoo:
  hhj
Grest
2022-09-13
Grest
.

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2267531803?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-13 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2267531803","market":"us","top_or_hot":-1,"title":"Akero's Shares Soared 137% as Experimental NASH Drug Meets The Primary Endpoint In A Clinical Trial","media":"Dow Jones","content":"<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a> Inc.  soared 137.57% in premarket trading on Tuesday after the company said its experimental treatment for nonalcoholic steatohepatitis met a primary and secondary endpoint in a Phase 2b clinical trial.</p><p><img src=\"https://static.tigerbbs.com/3928b3f6fa70cd5206a0fdab819a24f1\" tg-width=\"828\" tg-height=\"831\" referrerpolicy=\"no-referrer\"/></p><p>NASH is a liver disease. &#34;The magnitude and general consistency of results observed across the Phase 2a BALANCED and Phase 2b HARMONY studies increase the probability of success in Phase 3 and position EFX to potentially be a foundational monotherapy for patients with NASH,&#34; Dr. Stephen Harrison, one of the study&#39;s investigators, said in a news release.</p><p>Akero&#39;s stock is down 42.0% this year through Monday&#39;s close, while the broader S&amp;P 500  has declined 13.7%.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akero's Shares Soared 137% as Experimental NASH Drug Meets The Primary Endpoint In A Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkero's Shares Soared 137% as Experimental NASH Drug Meets The Primary Endpoint In A Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n2022-09-13 21:01 北京时间&nbsp;&nbsp;&nbsp;<strong>Dow Jones</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Akero Therapeutics Inc.  soared 137.57% in premarket trading on Tuesday after the company said its experimental treatment for nonalcoholic steatohepatitis met a primary and secondary ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKRO","symbol_name":"Akero Therapeutics","start_time":0,"source_url":"","article_id":"2267531803","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2267531803","pubTimestamp":1663074105,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Akero Therapeutics Inc.  soared 137.57% in premarket trading on Tuesday after the company ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKRO":"Akero Therapeutics"},"translate_title":"Akero的股价飙升137%，因为实验性纳什药物符合临床试验的主要终点","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":0.9},"content_text":"Shares of Akero Therapeutics Inc.  soared 137.57% in premarket trading on Tuesday after the company said its experimental treatment for nonalcoholic steatohepatitis met a primary and secondary endpoint in a Phase 2b clinical trial.NASH is a liver disease. \"The magnitude and general consistency of results observed across the Phase 2a BALANCED and Phase 2b HARMONY studies increase the probability of success in Phase 3 and position EFX to potentially be a foundational monotherapy for patients with NASH,\" Dr. Stephen Harrison, one of the study's investigators, said in a news release.Akero's stock is down 42.0% this year through Monday's close, while the broader S&P 500  has declined 13.7%.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9935243902,"gmtCreate":1663111412007,"gmtModify":1676537203548,"author":{"id":"4087513826666000","authorId":"4087513826666000","name":"evauoz","avatar":"https://static.tigerbbs.com/280532533b0476328d845887d7308f4d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087513826666000","authorIdStr":"4087513826666000"},"htmlText":"Buy?","listText":"Buy?","text":"Buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9935243902","repostId":2267531803,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9935631759,"gmtCreate":1663078731771,"gmtModify":1676537198298,"author":{"id":"4093950814016130","authorId":"4093950814016130","name":"lilynguyen","avatar":"https://static.tigerbbs.com/66ae1c34ce2f11e02f163e3f5d86c864","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"4093950814016130","authorIdStr":"4093950814016130"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9935631759","repostId":2267531803,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9935695980,"gmtCreate":1663077978940,"gmtModify":1676537198043,"author":{"id":"3581501341719005","authorId":"3581501341719005","name":"KYBoo","avatar":"https://static.tigerbbs.com/43072e3bdf1be8a6c0fb9e0d7c8a0558","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581501341719005","authorIdStr":"3581501341719005"},"htmlText":"Hjhh","listText":"Hjhh","text":"Hjhh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9935695980","repostId":2267531803,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103905679,"gmtCreate":1663077987211,"gmtModify":1663258800836,"authorId":3581501341719005,"author":{"id":3581501341719005,"idStr":"3581501341719005","authorId":3581501341719005,"name":"KYBoo","avatar":"https://static.tigerbbs.com/43072e3bdf1be8a6c0fb9e0d7c8a0558","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9935695980,"type":1,"supId":0,"prevId":0,"content":"<u>hhj</u>","text":"<u>hhj</u>","html":"<u>hhj</u>"}],"langContent":"EN"},{"id":9935845442,"gmtCreate":1663074330486,"gmtModify":1676537196846,"author":{"id":"3581503320247876","authorId":"3581503320247876","name":"Grest","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581503320247876","authorIdStr":"3581503320247876"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9935845442","repostId":2267531803,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":77,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2267531803"}